Compare Cytokinetics Inc (CYTK) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Firy Inc. — how do they compare? Cytokinetics Inc trades at $82.35 (market cap $11.12B), while Firy Inc. trades at $8.54 (market cap $125.48M). The key difference: Cytokinetics Inc is far larger — about 88.6× Firy Inc.'s market cap, and Cytokinetics Inc is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| CYTK | FIRY | |
|---|---|---|
Market Cap | $11.12B | $125.48M |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $12.45 |
52-Week Low | $33.23 | $2.28 |
Enterprise Value | $11.59B | $69.16M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
FIRY trades at $8.44, down 1.17% on the day, with a bullish technical signal from moving averages despite recent price weakness. The company reported Q1 2026 revenue growth but continues to post significant losses, with a net income margin of -57.48%. Recent developments include a corporate rebrand from Skillz Inc. and a major legal victory, though cash flow remains negative.
The outlook remains challenging due to persistent unprofitability and negative cash flows, offset by potential from the rebrand and legal win. Risks include high burn rate and competitive pressures. Analyst sentiment is mixed with a hold-dominated consensus, suggesting cautious optimism pending sustained operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
